Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Pennsylvania: - UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
- Carlisle Regional Cancer Center — Carlisle, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Chambersburg Hospital — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Pennsylvania: - Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Geisinger Medical Center-Cancer Center Hazleton — Hazleton, Pennsylvania
- Geisinger Medical Oncology-Lewisburg — Lewisburg, Pennsylvania
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Pennsylvania: - Chambersburg Hospital — Chambersburg, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Ephrata Cancer Center — Ephrata, Pennsylvania
- Adams Cancer Center — Gettysburg, Pennsylvania
- Sechler Family Cancer Center — Lebanon, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Pennsylvania: - Saint Vincent Hospital — Erie, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- Allegheny Valley Hospital — Natrona Heights, Pennsylvania
- Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Pennsylvania: - MidLantic urology — Bala-Cynwyd, Pennsylvania
- The Centers for Advanced Urology d/b/a Keystone Urology Specialist — Lancaster, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Pennsylvania: - Lehigh Valley Hospital — Allentown, Pennsylvania
- MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Keystone Urology Specialists — Lancaster, Pennsylvania
- Penn Medicine Abramson Cancer Center — Philadelphia, Pennsylvania
- UPMC Cancer Centers — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Pennsylvania: - Perelman Center for Advanced Medicine ( Site 0067) — Philadelphia, Pennsylvania
- Abramson Cancer Center - Penn Medicine ( Site 0079) — Philadelphia, Pennsylvania
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Sites in Pennsylvania: - Geisinger Cancer Center Dickson City — Dickson City, Pennsylvania
- Community Medical Center — Scranton, Pennsylvania
- Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Pennsylvania: - AHN Allegheny General Hospital ( Site 0001) — Pittsburgh, Pennsylvania
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Sites in Pennsylvania: - Saint Vincent Hospital — Erie, Pennsylvania
- Jefferson Hospital — Jefferson Hills, Pennsylvania
- Forbes Hospital — Monroeville, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- West Penn Hospital — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Pennsylvania: - Research Site — Hershey, Pennsylvania
- Research Site — Lancaster, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prosta…
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT07052214
Sites in Pennsylvania: - MidLantic Urology — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Pennsylvania: - Guthrie Medical Group PC-Robert Packer Hospital — Sayre, Pennsylvania
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Pennsylvania: - Corporal Michael J. Crescenz VA Medical Center — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended…
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06600698
Sites in Pennsylvania: - Penn State Cancer Institute — Hershey, Pennsylvania
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Pennsylvania: - Exelixis Clinical Site #104 — Hershey, Pennsylvania
- Exelixis Clinical Site #98 — Philadelphia, Pennsylvania
- Exelixis Clinical Site #32 — Pittsburgh, Pennsylvania
- Exelixis Clinical Site #24 — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…
Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
- Thomas Jefferson University Honickman Center — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
Phase 1 Recruiting Industry
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05413421
Sites in Pennsylvania: - MidLantic Urology — Bala-Cynwyd, Pennsylvania
- Keystone Urology Specialists — Lancaster, Pennsylvania
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive …
Sponsor: Eli Lilly and Company
NCT ID: NCT07114601
Sites in Pennsylvania: - University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Sponsor: Amgen
NCT ID: NCT07493512
Sites in Pennsylvania: - Thomas Jefferson University — Philadelphia, Pennsylvania
- University of Pittsburgh Medical Center Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 1 Recruiting Industry
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Pennsylvania: - Sidney Kimmel Cancer Center - Jefferson Health — Philadelphia, Pennsylvania